Drug Oncology

Abiraterone Acetate

Payments companies reported to CMS as associated with Abiraterone Acetate. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3,081associated payments (2023-2025)

73clinicians with associated payments

5companies reporting

By year

2023 $2,775

2024 $88.61

2025 $218

Payments reported as associated with Abiraterone Acetate, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Urology $664

Orthopaedic Trauma $382

Nurse Practitioner $250

Orthopaedic Surgery of The Spine $217

Hematology & Oncology $214

Family $203

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Abiraterone Acetate

These are the largest totals companies reported as associated with Abiraterone Acetate. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Andrew Bachinskas	Seattle, WA	Orthopaedic Surgery of The Spine	$217.42
Debbie Ali	North Miami, FL	Optometrist	$150.00
Gillian Soles	Sacramento, CA	Orthopaedic Surgery	$127.25
Augustine Saiz	Sacramento, CA	Orthopaedic Trauma	$127.25
Mark Lee	Sacramento, CA	Orthopaedic Trauma	$127.25
Ellen Fitzpatrick	Sacramento, CA	Orthopaedic Trauma	$127.25
Rajwanth Veluswamy	New York, NY	Medical Oncology	$120.39
Michael Avaricio	Ozone Park, NY		$101.14
Olubayo Tojuola	Orlando, FL	Urology	$89.00
Brian Bennett	Raleigh, NC	Urology	$78.04

Prescribed Abiraterone Acetate?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.